Sana Biotechnology

SANA

Market cap $918M

Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.

Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.

Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving a sharp rally but underscoring early-stage risk and manufacturing challenges. With a $1B valuation and limited cash runway to YE26, SANA will likely require further dilution to fund pivotal clinical trials.

Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst going forward. In my view, this is their make-or-break catalyst this year. A favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1.

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript